---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107013"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:11:38.999681+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026

## Summary
- Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).
- Net loss $12.9M ($0.49/share) vs $13.1M ($0.57/share) in Q3 2024; per-share loss improved.
- U.S. active implanting centers reached 250, up 20% year-over-year.
- CMS finalized Category I CPT codes for Barostim, improving patient access and removing adoption barriers.
- FY2025 guidance: revenue $55.6M-$56.6M (narrowed from $55M-$57M), gross margin 85%-86% (raised from 83%-84%).

## SEC filing metadata
- accession: 0001104659-25-107013
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/0001104659-25-107013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/tm2530302d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107013
- JSON: https://secwatch.observer/filing/0001104659-25-107013.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.